Cichowski Lab

Brigham & Women's Hospital | Harvard Medical School

Selected Publications




Co-targeting a MYC-eIF4A survival axis improves the efficacy of KRAS inhibitors in lung cancer


Francesca Nardi, Naiara Perurena, Amy E. Schade, Ze-Hua L, Kenneth Ngo, Elena V. Ivanova, Aisha Saldanha, Chendi Li, Prafulla C. Gokhale, Aaron N. Hata, David A. Barbie, Cloud P. Paweletz, Pasi A. Janne, Karen Cichowski

Journal of Clinical Investigation, 2023




DAB2IP is a bifunctional tumor suppressor that regulates wildtype RAS and inflammatory cascades in KRAS mutant colon cancer


Abigail L. Miller, Naiara Perurena, Alycia Gardner, Toshinori Hinoue, Patrick Loi, Peter W. Laird, Karen Cichowski

Cancer Research, 2023 May 18




USP9X mediates an acute adaptive response to MAPK suppression in pancreatic cancer but creates multiple actionable therapeutic vulnerabilities


Naiara Perurena, Rebecca Lock, Rachel A. Davis, Srivatsan Raghavan, Natalie F. Pilla, Raymond Ng, Patrick Loi, Caroline J. Guild, Abigail L. Miller, Ewa Sicinska, James M. Cleary, Douglas A. Rubinson, Brian M. Wolpin, Nathanael S. Gray, Sandro Santagata, William C. Hahn, Jennifer P. Morton, Owen J. Sansom, Andrew J. Aguirre, Karen Cichowski

Cell Reports Medicine, 2023 Apr




Combating castration-resistant prostate cancer by co-targeting the epigenetic regulators EZH2 and HDAC


Amy E. Schade, Ryan Kuzmickas, Carrie L. Rodriguez, Kaia Mattioli, Miriam Enos, Alycia Gardner, Karen Cichowski

PLOS Biology, vol. 21, Public Library of Science, 2023 Apr, pp. 1-21




A Deregulated HOX Gene Axis Confers an Epigenetic Vulnerability in KRAS-Mutant Lung Cancers


Stephanie L. Guerra, Ophélia Maertens, Ryan Kuzmickas, Thomas De Raedt, Richard O. Adeyemi, Caroline J. Guild, Shawna Guillemette, Amanda J. Redig, Emily S. Chambers, Man Xu, Hong Tiv, Sandro Santagata, Pasi A. Jänne, Stephen J. Elledge, Karen Cichowski

Cancer Cell, vol. 37, 2020, pp. 705-719.e6


MAPK Pathway Suppression Unmasks Latent DNA Repair Defects and Confers a Chemical Synthetic Vulnerability in BRAF-, NRAS-, and NF1-Mutant Melanomas


Ophélia Maertens, Ryan Kuzmickas, Haley E. Manchester, Chloe E. Emerson, Alessandra G. Gavin, Caroline J. Guild, Terence C. Wong, Thomas De Raedt, Christian Bowman-Colin, Elodie Hatchi, Levi A. Garraway, Keith T. Flaherty, Shailja Pathania, Stephen J. Elledge, Karen Cichowski

Cancer Discovery, vol. 9, 2019 Apr, pp. 526-545


mTOR and HDAC Inhibitors Converge on the TXNIP/Thioredoxin Pathway to Cause Catastrophic Oxidative Stress and Regression of RAS-Driven Tumors


Clare F. Malone, Chloe Emerson, Rachel Ingraham, William Barbosa, Stephanie Guerra, Haejin Yoon, Lin L. Liu, Franziska Michor, Marcia Haigis, Kay F. Macleod, Ophélia Maertens, Karen Cichowski

Cancer Discovery, vol. 7, 2017 Dec, pp. 1450-1463


A Collaborative Model for Accelerating the Discovery and Translation of Cancer Therapies


Ophélia Maertens, Mila E. McCurrach, Benjamin S. Braun, Thomas De Raedt, Inbal Epstein, Tannie Q. Huang, Jennifer O. Lauchle, Hyerim Lee, Jianqiang Wu, Timothy P. Cripe, D. Wade Clapp, Nancy Ratner, Kevin Shannon, Karen Cichowski

Cancer Research, vol. 77, 2017 Oct, pp. 5706-5711


Loss of RasGAP Tumor Suppressors Underlies the Aggressive Nature of Luminal B Breast Cancers


Sarah Naomi Olsen, Ania Wronski, Zafira Castaño, Benjamin Dake, Clare Malone, Thomas De Raedt, Miriam Enos, Yoko S. DeRose, Wenhui Zhou, Stephanie Guerra, Massimo Loda, Alana Welm, Ann H. Partridge, Sandra S. McAllister, Charlotte Kuperwasser, Karen Cichowski

Cancer Discovery, vol. 7, 2017 Feb, pp. 202-217


Cotargeting MNK and MEK kinases induces the regression of NF1-mutant cancers


Rebecca Lock, Rachel Ingraham, Ophélia Maertens, Abigail L. Miller, Nelly Weledji, Eric Legius, Bruce M. Konicek, Sau-Chi B. Yan, Jeremy R. Graff, Karen Cichowski

The Journal of Clinical Investigation, vol. 126, The American Society for Clinical Investigation, 2016 Jun, pp. 2181-2190

Share



Follow this website


You need to create an Owlstown account to follow this website.


Sign up

Already an Owlstown member?

Log in